Brief: Otsuka And Lundbeck Receive Complete Response Letter From U.S. FDA For SNDA Of Rexulti® (Brexpiprazole) In Combination With Sertraline For The Treatment Of Adults With PTSD
20/09/2025 07:04
Sept 20 (Reuters) - H Lundbeck A/S HLUNa.CO and Otsuka 4578.T: OTSUKA AND LUNDBECK RECEIVE COMPLETE RESPONSE LETTER FROM U.S. FDA FOR SNDA OF REXULTI® (BREXPIPRAZOLE) IN COMBINATION WITH SERTRALINE FOR THE TREATMENT OF ADULTS WITH PTSD Source text: ID:nWkr7RKxzf Further company coverage: [HLUNa.CO] ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug